Hypocalcemia Management in End-Stage Renal Disease

Pathophysiology and Prevalence

Patients with End-Stage Renal Disease (ESRD) develop hypocalcemia due to reduced intestinal calcium absorption, phosphate retention, and resistance to parathyroid hormone (PTH) action 1
The National Kidney Foundation suggests that phosphate retention leads to calcium-phosphate precipitation, contributing to hypocalcemia 1
The American Journal of Kidney Diseases states that resistance to parathyroid hormone (PTH) action is a mechanism of hypocalcemia in ESRD patients 1
Dialysate calcium concentration that may be insufficient to maintain calcium balance can also contribute to hypocalcemia 3, 4

Hypocalcemia contributes to the pathogenesis of secondary hyperparathyroidism and renal osteodystrophy, according to the Annals of Internal Medicine 5
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest an individualized approach to treating hypocalcemia rather than recommending correction in all ESRD patients 5
Treatment is indicated for symptomatic hypocalcemia, significantly low calcium levels, and elevated PTH levels above target range for CKD stage 1, 6
The American Journal of Kidney Diseases recommends oral calcium supplementation, vitamin D supplementation, and active vitamin D sterols as treatment options for hypocalcemia 6
Adjusting dialysate calcium concentration to 1.50 mmol/L or higher in patients on long or long-frequent hemodialysis is also a treatment option 3, 4

The National Kidney Foundation recommends monitoring serum calcium and phosphorus at least every 3 months during treatment 6
Maintaining calcium-phosphorus product <55 mg²/dL² can reduce the risk of soft tissue calcification, according to the American Journal of Kidney Diseases 1, 2
Calcium balance in ESRD patients is affected by multiple factors, including the use of calcium-based phosphate binders, frequency of hemodialysis, ultrafiltration volumes, and dialysate calcium concentration 3